Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM8S6T7)

Drug Name
Ivosidenib Drug Info
Synonyms
UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767
Cross-matching ID
PubChem CID
71657455
ChEBI ID
CHEMBL3989958
CAS Number
CAS 1448347-49-6
TTD Drug ID
D07DCG
ACDINA Drug ID
D01187

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Steroid hormone biosynthesis 1.80 9.36e-2 43/61 (70.49%) AKR1C3;CYP1B1;UGT2B15;...
Ovarian steroidogenesis 1.78 6.69e-2 41/51 (80.39%) AKR1C3;CYP1B1;SCARB1;...
Amoebiasis 1.75 7.13e-2 99/102 (97.06%) COL3A1;CXCL1;CASP3;...
Toxoplasmosis 1.70 9.36e-2 103/112 (91.96%) CASP3;BIRC2;AKT1;...
FoxO signaling pathway 1.69 8.83e-2 118/131 (90.08%) AKT1;TNFSF10;TGFB1;...
TGF-beta signaling pathway 1.68 8.91e-2 81/94 (86.17%) TGFB1;TGFBR2;ID1;...
Apelin signaling pathway 1.66 1.15e-1 117/137 (85.4%) GNG11;AKT1;CCN2;...
Platelet activation 1.64 1.30e-1 106/124 (85.48%) COL3A1;COL1A1;AKT1;...
Chronic myeloid leukemia 1.64 1.17e-1 72/76 (94.74%) MECOM;AKT1;TGFB1;...
Ribosome 1.63 1.18e-1 113/158 (71.52%) RPS5;MRPL12;RPS27L;...
Fat digestion and absorption 1.63 1.07e-1 35/43 (81.4%) SCARB1;CD36;APOA1;...
Bile secretion 1.62 1.04e-1 68/90 (75.56%) KCNN2;ABCC4;CA2;...
mTOR signaling pathway 1.62 1.10e-1 114/154 (74.03%) FZD5;AKT1;NPRL2;...
Signaling pathways regulating pluripotency of stem cell... 1.62 1.02e-1 110/143 (76.92%) FZD5;AKT1;PCGF3;...
Relaxin signaling pathway 1.61 9.63e-2 114/129 (88.37%) COL3A1;GNG11;COL1A1;...
Melanogenesis 1.61 9.19e-2 74/101 (73.27%) FZD5;FZD10;GNAI1;...
Small cell lung cancer 1.58 1.13e-1 90/92 (97.83%) CASP3;BIRC2;AKT1;...
Basal cell carcinoma 1.57 1.23e-1 41/63 (65.08%) FZD5;FZD10;BMP2;...
Pathways in cancer 1.53 1.45e-1 474/531 (89.27%) CXCR4;GNG11;CASP3;...
Allograft rejection 1.53 1.44e-1 32/38 (84.21%) HLA-DOB;HLA-DPB1;HLA-C;...
cGMP-PKG signaling pathway 1.53 1.39e-1 145/167 (86.83%) AKT1;BAD;ADRB2;...
Graft-versus-host disease 1.52 1.38e-1 32/42 (76.19%) HLA-DOB;HLA-DPB1;HLA-C;...
p53 signaling pathway 1.51 1.46e-1 63/73 (86.3%) CASP3;CCNG2;CDKN2A;...
Glycosylphosphatidylinositol (GPI)-anchor biosynthesis 1.49 1.67e-1 20/26 (76.92%) PIGF;PIGG;GPAA1;...
Breast cancer 1.47 1.81e-1 119/147 (80.95%) FZD5;AKT1;NOTCH1;...
Adipocytokine signaling pathway 1.47 1.75e-1 64/69 (92.75%) NPY;CAMKK2;AKT1;...
Progesterone-mediated oocyte maturation 1.42 1.82e-1 75/100 (75%) AKT1;MAD1L1;GNAI1;...
Cushing syndrome 1.42 1.82e-1 125/155 (80.65%) FZD5;SCARB1;FZD10;...
Thyroid hormone signaling pathway 1.42 1.78e-1 112/121 (92.56%) AKT1;BAD;NOTCH1;...
Ascorbate and aldarate metabolism 1.42 1.75e-1 15/30 (50%) UGT2B15;UGT2B17;ALDH3A2;...
RNA transport -1.14 5.55e-1 128/186 (68.82%) EIF1AX;POP1;EIF4EBP2;...
Adherens junction -1.15 5.49e-1 63/71 (88.73%) SORBS1;PTPN1;CSNK2A2;...
Vasopressin-regulated water reabsorption -1.24 5.18e-1 40/44 (90.91%) CREB3;DCTN1;CREB3L1;...
Mitophagy -1.24 5.36e-1 56/68 (82.35%) MRAS;ATF4;OPTN;...
Phenylalanine metabolism -1.24 5.34e-1 14/17 (82.35%) GLYAT;HPD;GOT1;...
Homologous recombination -1.26 5.09e-1 35/41 (85.37%) MUS81;RAD54L;BRCA2;...
Propanoate metabolism -1.28 4.46e-1 30/34 (88.24%) ECHS1;ABAT;SUCLG1;...
Peroxisome -1.29 4.43e-1 72/82 (87.8%) ACSL5;PEX26;AGPS;...
Tight junction -1.29 4.59e-1 130/169 (76.92%) RAB8A;CLDN1;ARPC3;...
Carbohydrate digestion and absorption -1.30 4.71e-1 37/47 (78.72%) HK1;PRKCB;SLC5A1;...
Thyroid hormone synthesis -1.31 4.45e-1 66/75 (88%) PRKCA;ATF4;ADCY3;...
One carbon pool by folate -1.34 4.02e-1 15/20 (75%) GART;AMT;ATIC;...
Central carbon metabolism in cancer -1.34 4.07e-1 67/70 (95.71%) IDH2;GLS2;PFKP;...
Biosynthesis of unsaturated fatty acids -1.34 4.26e-1 21/27 (77.78%) HACD3;ELOVL5;ACOT7;...
Circadian rhythm -1.36 4.01e-1 26/31 (83.87%) CRY2;PRKAA1;NPAS2;...
Nucleotide excision repair -1.37 3.98e-1 40/47 (85.11%) ERCC1;GTF2H5;XPA;...
Neomycin, kanamycin and gentamicin biosynthesis -1.39 3.56e-1 5/5 (100%) GCK;HK1;HK3
Arginine and proline metabolism -1.45 2.48e-1 39/50 (78%) ALDH9A1;AMD1;CNDP2;...
Glyoxylate and dicarboxylate metabolism -1.46 2.49e-1 23/30 (76.67%) GLDC;CS;MDH2;...
Mismatch repair -1.47 2.48e-1 22/23 (95.65%) LIG1;POLD1;MSH6;...
Arginine biosynthesis -1.52 1.67e-1 17/22 (77.27%) ASS1;ARG2;GLUD2;...
Ubiquinone and other terpenoid-quinone biosynthesis -1.54 1.61e-1 9/11 (81.82%) TAT;COQ7;COQ3;...
Cocaine addiction -1.54 1.70e-1 42/49 (85.71%) GRIN2A;ATF4;BDNF;...
Nicotine addiction -1.57 1.49e-1 32/40 (80%) SLC17A6;CHRNA4;GABRA4;...
Glycine, serine and threonine metabolism -1.60 1.39e-1 31/40 (77.5%) GRHPR;GCAT;AMT;...
DNA replication -1.62 1.41e-1 34/36 (94.44%) POLA1;RFC4;SSBP1;...
Alanine, aspartate and glutamate metabolism -1.63 1.54e-1 27/37 (72.97%) ABAT;ASS1;ALDH4A1;...
Pentose phosphate pathway -1.64 1.98e-1 25/30 (83.33%) FBP1;RGN;TKTL1;...
Citrate cycle (TCA cycle) -1.81 6.15e-2 30/30 (100%) SUCLA2;CS;IDH2;...
Mineral absorption -1.84 6.83e-2 48/60 (80%) SLC5A1;HMOX1;MT1H;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SK-ES-1 CVCL_0627 Homo sapiens 1.11uM - 10uM 24H
Brain
Glioma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
GI-1 CVCL_1230 Homo sapiens 1.11uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MDA-MB-468 CVCL_0419 Homo sapiens 1.11uM - 10uM 24H
Breast ductal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
T-47D CVCL_0553 Homo sapiens 1.11uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SNU-407 CVCL_5004 Homo sapiens 1.11uM - 10uM 24H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 1.11uM - 10uM 24H
HEC-1-A CVCL_0293 Homo sapiens 1.11uM - 10uM 24H
HEC-251 CVCL_2928 Homo sapiens 1.11uM - 10uM 24H
HEC-265 CVCL_2929 Homo sapiens 1.11uM - 10uM 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CJM CVCL_U797 Homo sapiens 1.11uM - 10uM 24H
Liver
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHH-5 CVCL_1320 Homo sapiens 1.11uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1573 CVCL_1483 Homo sapiens 1.11uM - 10uM 24H
NCI-H838 CVCL_1594 Homo sapiens 1.11uM - 10uM 24H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BEN CVCL_1081 Homo sapiens 1.11uM - 10uM 24H
HCC95 CVCL_1276 Homo sapiens 1.11uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H2110 CVCL_1529 Homo sapiens 1.11uM - 10uM 24H
Muscle
Rhabdomyosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-204 CVCL_0134 Homo sapiens 1.11uM - 10uM 24H
Ovary
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
OVTOKO CVCL_3114 Homo sapiens 1.11uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
22Rv1 CVCL_1045 Homo sapiens 1.11uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
IGR-37 CVCL_1303 Homo sapiens 1.11uM - 10uM 24H
Mel-HO CVCL_1402 Homo sapiens 1.11uM - 10uM 24H
SH-4 CVCL_1692 Homo sapiens 1.11uM - 10uM 24H
Urinary bladder
Bladder transitional cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CAL-29 CVCL_1109 Homo sapiens 1.11uM - 10uM 24H